Collplant Biotechnologies Ltd

NASDAQ CLGN

Data sourced from

and

Download Data

Collplant Biotechnologies Ltd EBIT to Total Assets Ratio 1 year YoY Change (%) for the quarter ending March 31, 2024: -50.91%

Collplant Biotechnologies Ltd EBIT to Total Assets Ratio 1 year YoY Change (%) is -50.91% for the quarter ending March 31, 2024, a -91.68% change year over year. The EBIT to Total Assets Ratio measures a company's operating earnings (EBIT) generated per dollar of total assets. It shows how efficiently a company utilizes its assets to generate earnings. A higher ratio indicates better asset utilization and profitability. It reflects the ability of a company to generate earnings from its invested assets and is useful in assessing operational efficiency and financial performance. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.

Collplant Biotechnologies Ltd EBIT to Total Assets Ratio for the quarter ending March 31, 2023 was -0.10, a -27.25% change year over year.
Collplant Biotechnologies Ltd EBIT to Total Assets Ratio for the quarter ending March 31, 2022 was -0.08, a -143.47% change year over year.
Collplant Biotechnologies Ltd EBIT to Total Assets Ratio for the quarter ending March 31, 2021 was 0.18, a 113.74% change year over year.
Collplant Biotechnologies Ltd EBIT to Total Assets Ratio for the quarter ending March 31, 2020 was 0.08, a 34.73% change year over year.

NASDAQ: CLGN

Collplant Biotechnologies Ltd

CEO	Mr. Yehiel Tal
IPO Date	Jan. 30, 2018
Location	Israel
Headquarters	Weizmann Science Park, Rehovot, Israel, 7670104
Employees	75
Sector	Healthcare
Industry	Biotechnology

Description

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company's products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures. It has collaboration agreements with Advanced Regenerative Manufacturing Institute; RegenMed Development Organization; International Society for Biofabrication; AbbVie; and STEMCELL Technologies. The company was formerly known as CollPlant Holdings Ltd. and changed its name to CollPlant Biotechnologies Ltd. in June 2019. The company was founded in 2004 and is headquartered in Rehovot, Israel.

Key trends